期刊
HEALTH ECONOMICS
卷 18, 期 7, 页码 807-821出版社
WILEY
DOI: 10.1002/hec.1404
关键词
Bayesian model averaging; cost data; health economics; MCMC; sensitivity analysis
We consider the problem of assessing new and existing technologies for their cost-effectiveness ill the case where data on both costs and effects are available from,I clinical trial, and we address it by means of the cost-effectiveness acceptability curve. The main difficulty in these analyses is that cost data usually exhibit highly skew and heavy-tailed distributions so that it call be extremely difficult to produce realistic probabilistic models for the underlying population distribution, and in particular to model accurately the tail of the distribution, which is highly influential in estimating the population mean. Here. in order to integrate the uncertainty about the model into the analysis of cost data and into cost-effectiveness analyses, we consider all approach based oil Bayesian model averaging: instead of choosing a single parametric model, we specify a set of plausible models for costs and estimate the mean cost with a weighted mean of its posterior expectations under each model, with weights given by the posterior model probabilities. The results are compared with those obtained with a semi-parametric approach that does not require an), assumption about the distribution of costs. Copyright (c) 2008 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据